Suggestions on the usage, dosage and dosage adjustment of Asnib/Asiminib

Asciminib (Asciminib) is a selective BCR-ABL1 inhibitor (STAMP inhibitor), mainly used for treatment It is especially suitable for patients with chronic myeloid leukemia (CML) in the chronic phase or accelerated phase, especially for patients who are resistant or intolerant to traditionalTKI (imatinib, dasatinib or nilotinib). Its mechanism of action is different from traditional ATP binding pocket inhibitors. It achieves selective inhibition by combining with the "myristoyl pocket" of Abltyrosine kinase and can exert efficacy in drug-resistant patients.

Standard usage and dosage: The conventional recommended dose for adult patients is 40 mgorally twice a day (BID), or it can be adjusted to 80 mg once a day (QD) according to the patient's specific tolerance. The tablet should be swallowed whole, with or without food, but it is recommended to take it at the same time every day to maintain stable blood concentration.

Recommendations for dose adjustment: If during treatment, moderate to severe hematological toxicity (such as neutropenia, thrombocytopenia) or non-hematological intolerable side effects (such as abnormal liver function, arrhythmia), the dose can be halved or the drug temporarily discontinued, and the original dose can be restored after the indicators return to an acceptable range. For patients who are concomitant with strong CYP3A4 inhibitors or inducers, dose adjustments may also be necessary to avoid drug accumulation or reduced efficacy.

During the treatment, it is recommended to regularly monitor blood routine, liver and kidney function and electrocardiogram, especially 3 months before treatment, and follow-up every 2–4 weeks to evaluate drug tolerance and efficacy. For patients undergoing long-term maintenance treatment, the frequency of monitoring can be gradually reduced based on blood picture stability and clinical response, but regular follow-up is still required to ensure safety and efficacy.

Reference materials:https://www.drugs.com/